Bioimplant formulation

Abstract

A pharmaceutical and/or veterinary formulation comprising about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-forming agent and the balance stearin. Such formulations provide sustained release of the at least one active agent in humans and other animals for periods of 7 days up to about 2 years.

1 - 40 . (canceled)  
     
     
         41 . A pharmaceutical and/or veterinary formulation comprising about 2-30% (w/w) (on an active basis) of at least one active agent, about 0.5-20.0% (w/w) of a pore-forming agent comprising lecithin and an organic salt, and the balance stearin.  
     
     
         42 . A formulation according to  claim 41 , wherein the formulation comprises about 5-10% (w/w) (on an active basis) of the at least one active agent, about 1.0-10.0% (w/w) of the pore-forming agent and the balance stearin.  
     
     
         43 . A formulation according to  claim 41 , wherein the formulation comprises about 5-10% (w/w) (on an active basis) of the at least one active agent. about 2.0-5.0% (w/w) of the pore-forming agent and the balance stearin.  
     
     
         44 . A formulation according to  claim 41 , wherein the pore-forming agent comprises lecithin and sodium acetate.  
     
     
         45 . A formulation according to  claim 41 , wherein the at least one active agent is selected from peptides, polypeptides, proteins and nucleic acid compounds and derivatives.  
     
     
         46 . A formulation according to  claim 41 , wherein the at least one active agent is selected from GnRII agonists.  
     
     
         47 . A formulation according to  claim 46 , wherein the GnRH agonist(s) is selected from deslorelin, eulexin, goserelin, leuprolide. dioxalan derivatives, triptorelin, mieterelin, buserelin, histerlin, nafarelin, lutrelm, leuprorelin and LIIRII analogues.  
     
     
         48 . A formulation according to  claim 46 , wherein the GnRII agonist(s) is deslorelin and the pore-forming agent comprises lecithin and sodium acetate.  
     
     
         49 . A formulation according to  claim 41 , wherein the at least one active agent has a log octanol/water partition coefficient (log P) in the range of 5.0 to −3.0.  
     
     
         50 . A formulation according to  claim 49 , wherein the at least one active agent has a log octanol/water partition coefficient (log P) in the range 1.0 to −3.0.  
     
     
         51 . A formulation according to  claim 41 , wherein the formulation is in the form of free flowing beads or rods.  
     
     
         52 . A method of treating a disease or condition in a human or other animal, the method comprising administering to the human or other animal a formulation according to  claim 41.